Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Donepezil on Glycemic Control in Type II Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over the age of 50 with Type 2 Diabetes Mellitus, regardless of co-morbidities including renal and vascular insufficiency, Cardiovascular Autonomic Neuropathy, Hypertension, Chronic Obstructive Pulmonary Disease or Coronary Disease will be selected.~Exclusion Criteria:~* Patients under the age of 50~* Patients who are pregnant or lactating~* Patients who are lactose intolerance~* Patients with an allergy to Donepezil~* Prothrombin Time and International Normalized Ratio value greater than 1.25~* Pre-menopausal women and patients allergic to Donepezil are excluded.

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil treatment group (Type: EXPERIMENTAL): Administration of 5mg or 10 mg of donepezil daily
- Control group (Type: PLACEBO_COMPARATOR): Administration of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).